John D. Quisel, Chief Executive Officer of Disc Medicine, Inc. (NASDAQ:IRON), completed a significant divestment of company stock on July 13, 2026. The transaction involved the sale of 33,000 shares, with the total value of the sale reaching approximately $2.47 million. The shares were disposed of at prices ranging between $73.62 and $76.29 per share. This sale was part of a broader set of transactions executed under a Rule 10b5-1 trading plan that was established on March 12, 2026. The plan allows for pre-arranged trading to mitigate conflicts of interest and ensure compliance with securities regulations.
The July 13 activity comprised three distinct sales events. In the first block, Mr. Quisel sold 9,704 shares at a weighted average price of $74.2729, with individual trade prices falling between $73.62 and $74.60. The second block involved the sale of 16,896 shares at a weighted average price of $74.9469, with prices ranging from $74.62 to $75.50. The final block consisted of 6,400 shares sold at a weighted average price of $76.0520, with transaction prices between $75.83 and $76.29. These sales were offset by the acquisition of an equivalent number of shares through stock option exercises.
Mr. Quisel exercised options to acquire 33,000 shares on the same day. The first exercise involved 25,584 shares at an exercise price of $9.86 per share. These options were fully vested and exercisable as of the transaction date. The second exercise covered 7,416 shares at an exercise price of $13.50 per share. These options vest in 48 equal monthly installments following December 29, 2022. Following these transactions, Mr. Quisel directly holds 226,064 shares of Disc Medicine common stock.
The insider sale occurs as IRON trades at $75.01, reflecting a nearly 30% increase over the past year. However, valuation analysis suggests the stock may be overvalued relative to its fair value. The stock exhibits high volatility, characterized by a beta of 2.07, which has influenced recent trading patterns. Investors seeking to understand the investment profile of IRON can access detailed valuation metrics and additional analysis tools.
Disc Medicine continues to advance its clinical pipeline. The company presented updated clinical trial data for its investigational treatments at the European Hematology Association Annual Meeting. The RALLY-MF trial, which enrolled 61 adult patients with myelofibrosis and anemia, demonstrated promising results with DISC-0974. The data showed efficacy in treating myelofibrosis-related anemia, regardless of baseline anemia severity. Stifel reiterated a Buy rating and set a $111.00 price target for Disc Medicine following the presentation of the Phase 2 RALLY-MF trial data.
Regulatory progress is also underway. Disc Medicine completed a Type A meeting with the FDA regarding bitopertin. It was agreed that the ongoing Phase 3 APOLLO study could potentially support a traditional approval if successful. The company expects to submit its response to the FDA’s Complete Response Letter by the end of 2026. Additionally, Disc Medicine launched an expanded access program for bitopertin in the U.S., targeting patients with erythropoietic protoporphyria and X-linked protoporphyria. This program provides access to the investigational treatment for eligible patients prior to regulatory approval.